Detecting disability using self-reported and clinical assessments in early-stage relapsing-remitting multiple sclerosis: Looking for a complementary approach
Sainz de la Maza, Susana ; Gómez-Ballesteros, Rocío ; Borges, Mónica ; Martín-Martínez, Jesús ; Sotoca, Javier ; Alonso, Ana ; Caminero, Ana B. ; Borrega, Laura ; Sánchez-Menoyo, José L. ; Barrero-Hernández, Francisco J. ; Calles, Carmen ; Brieva, Luis ; Blasco-Quílez, María R. ; Dotor García-Soto, Julio ; Campo-Amigo, María del ; Navarro-Cantó, Laura ; Agüera, Eduardo ; Garcés-Redondo, Moisés (Universidad de Zaragoza) ; Carmona, Olga ; Gabaldón-Torres, Laura ; Forero, Lucía ; Hervàs, Mariona ; Medrano, Nicolás ; Maurino, Jorge ; Castillo-Triviño, Tamara
Resumen: Disability accrual is mainly driven by progression independent of relapse activity, which is present even in early stages of relapsing-remitting multiple sclerosis (RRMS) and sometimes overlooked. This multicenter, non-interventional study evaluated whether patient-reported outcomes measures (PROMs) could capture disability in 189 early-stage RRMS patients (mean age: 36.1 ± 9.4 years, 71.4% female, mean disease duration: 1.4 ± 0.8 years, median EDSS: 1.0). The 9-Hole Peg Test (9-HPT), NeuroQoL Upper Extremity (NeuroQoL-UE), Timed 25-Foot Walk (T25-FW), Multiple Sclerosis Walking Scale (MSWS-12), Symbol Digit Modalities Test (SDMT), and Perceived Deficits Questionnaire (PDQ-5) were used to assess hand function, gait, and cognition, respectively. These functions were at least mildly affected in this early-stage population, finding significant correlations between PROMs and clinical assessments. PROMs could enable early-stage RRMS patients to communicate their perceived disability in different domains, assisting clinicians in disease monitoring and decision making.
Idioma: Inglés
DOI: 10.1177/20552173231169475
Año: 2023
Publicado en: Multiple Sclerosis Journal - Experimental, Translational and Clinical 9, 2 (2023), [7 pp.]
ISSN: 2055-2173
Factor impacto CITESCORE: 4.7 - Neurology (clinical) (Q2) - Cellular and Molecular Neuroscience (Q3)
Factor impacto SCIMAGO: 0.959 - Neurology (clinical) (Q2) - Cellular and Molecular Neuroscience (Q3)
Tipo y forma: Article (Published version)
Área (Departamento): Area Medicina (Dpto. Medicina, Psiqu. y Derm.)
You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. You may not use the material for commercial purposes.
Exportado de SIDERAL (2024-07-31-10:06:19)
Visitas y descargas
Idioma: Inglés
DOI: 10.1177/20552173231169475
Año: 2023
Publicado en: Multiple Sclerosis Journal - Experimental, Translational and Clinical 9, 2 (2023), [7 pp.]
ISSN: 2055-2173
Factor impacto CITESCORE: 4.7 - Neurology (clinical) (Q2) - Cellular and Molecular Neuroscience (Q3)
Factor impacto SCIMAGO: 0.959 - Neurology (clinical) (Q2) - Cellular and Molecular Neuroscience (Q3)
Tipo y forma: Article (Published version)
Área (Departamento): Area Medicina (Dpto. Medicina, Psiqu. y Derm.)
You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. You may not use the material for commercial purposes. Exportado de SIDERAL (2024-07-31-10:06:19)
Permalink:
Visitas y descargas
Este artículo se encuentra en las siguientes colecciones:
Articles > Artículos por área > Medicina
Record created 2024-02-19, last modified 2024-07-31